Enabling accurate quantitative small molecule biosensor assays with Optimer®
The accurate and sensitive detection of small molecules in point-of-care and in situ biosensor assays could enable faster and simpler analysis to extend diagnostic capabilities. The Optimer platform incorporates a discovery process that has been specifically designed to identify small molecule binding ligands.
Find out how:
- Optimer biosensors meet the strict FDA requirements for ligand binding assays
- Optimer ligands enable wearable and near-patient biosensors for small molecule drugs
- High analytical sensitivity and selectivity are being met in single-plex and multiplex Optimer biosensors for small molecule analytes
- Cross-validation with HPLC-MS shows excellent accuracy of Optimer biosensors